Venmax Drugs And Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has announced the closure of its trading window for all insiders, including designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed effective July 1, 2026, and will reopen forty-eight hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to consider these financial results will be intimated separately.

Venmax Drugs and Pharmaceuticals Ltd. confirms no deviation or variation in the use of proceeds raised through a preferential issue, as per Regulation 32 of SEBI guidelines. The funds, raised on March 20, 2025, were intended for working capital (₹10 crores) and general corporate purposes/business acquisition (₹10.05 crores). As of March 31, 2026, ₹8.12 crores was utilized for working capital and ₹0.20 crores for general corporate purposes. The Audit Committee reviewed and confirmed the utilization, with no deviations noted by auditors.

Venmax Drugs and Pharmaceuticals Ltd declared audited financial results for the quarter and year ended March 31, 2026. The company's revenue from operations for the year ended March 31, 2026, stood at ₹802.49 lakhs, compared to ₹80.73 lakhs in the previous year. The company reported a profit of ₹24.82 lakhs for the year ended March 31, 2026, compared to a loss of ₹1.05 lakhs in the previous year.

Venmax Drugs and Pharmaceuticals Ltd announced audited financial results for the quarter and year ended March 31, 2026. Revenue from operations for FY26 stood at ₹802.49 lakhs, compared to ₹80.73 lakhs in FY25. The company reported a profit of ₹24.82 lakhs for the year, a significant improvement from a loss of ₹1.05 lakhs in the previous year. The Board Meeting was held on May 14, 2026, where the results were approved.

Venmax Drugs and Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 14, 2026, to consider and approve the Audited Standalone Financial Results for the quarter and year ended March 31, 2026. The trading window, which has been closed since April 1, 2026, will remain closed until May 16, 2026, 48 hours after the approval of the results.

Venmax Drugs and Pharmaceuticals Ltd. has disclosed an annual declaration from its promoters under Regulation 31(4) of SEBI (SAST) Regulations, 2011. The promoters have confirmed that they have not made any encumbrance, directly or indirectly, on the shares held in the company for the financial year ended March 31, 2026. This disclosure was made to the Assistant General Manager, Chairman of the Department of Corporate Services Audit Committee, and the Bombay Stock Exchange.

Venmax Drugs and Pharmaceuticals Ltd has announced the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional Director, Non-Executive and Non-Independent Director, and Mr. Revoor Ramachandra as an Additional Director, Non-Executive and Independent Director. Mrs. Sadhanala, with over 20 years of experience in the pharmaceutical industry, will hold office until the conclusion of the next General/Annual General Meeting. Mr. Ramachandra, with over 42 years of experience in various industries, will serve for a term of five years, subject to the approval of the Members at the next General/Annual General Meeting.

Venmax Drugs and Pharmaceuticals Ltd, a company engaged in the trading of Nutraceuticals products and Drug Intermediates & Cosmetic Chemicals, announced that its Board of Directors approved the amendment in Para 2.2 of the Share Capital Clause in the Draft Scheme of Amalgamation with Hatri Pharma Private Limited. The amendment pertains to the Issued, Subscribed & Paid-Up Capital of Venmax Drugs and Pharmaceuticals Ltd. The company has issued 1,00,25,000 (One Crore Twenty-Five Thousand) convertible equity share warrants, out of which 63,44,000 equity shares have been allotted to warrant holders pursuant to conversion of warrants and the balance 36,81,000 equity shares are pending allotment upon conversion. This amendment would result in an increase in the issued, subscribed and paid-up equity share capital of the company upon exercise of the warrants by the holders.

Venmax Drugs and Pharmaceuticals Ltd has announced the closure of the trading window for all insiders, including designated persons and their immediate relatives, effective from April 1, 2026. This closure is in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading. The closure comes 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026. The date of the board meeting for the consideration of these results will be intimated in due course.

Venmax Drugs and Pharmaceuticals Ltd. has allotted 28,00,000 equity shares following the conversion of convertible warrants by two warrant holders. The allotment was made at an issue price of Rs. 20/- per share, which includes a face value of Rs. 10/- and a premium of Rs. 10/-. The allotment has increased the company's paid-up capital to Rs. 11,58,29,300. The warrant holders who exercised their conversion rights are Jugal Kishore Bhagat and Pushpa Bhaju, who were allotted 13,00,000 and 15,00,000 equity shares, respectively.